title: Details of hyperplastic polyps of the stomach shrinking after anti-Helicobacter pylori therapy.
abstract: The precise etiology of hyperplastic polyps of the stomach is unknown, but recent studies suggest that they arise as a consequence of inflammation occurring in intimate association with Helicobacter pylori infection. The process of polyp regression after anti-H. pylori therapy, however, is unclear. Here we report a patient with large hyperplastic polyps of the stomach that regressed markedly after anti-H. pylori therapy. Histological examination of the regressed polyps revealed a decrease in the height of the hyperplastic foveolar epithelium and a decrease in the amount of inflammatory cell infiltration in the stroma. In addition, the percentage of Ki-67-positive hyperplastic epithelial cells markedly decreased after anti-H. pylori therapy, indicating that the epithelial cell proliferation rate had markedly decreased after treatment. At the same time, the degree of cyclooxygenase-2 expression in epithelial cells in the polyps decreased after treatment. Because cyclooxygenase-2 is expressed at sites of inflammation or neoplasm, these findings are consistent with a decrease in inflammatory cell infiltration, and represent resolving inflammation.
authors.affiliation: The Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Nakajima
authors.forename: N
authors.initials: N
authors.lastname: Matsuhashi
authors.forename: Y
authors.initials: Y
authors.lastname: Yazaki
authors.forename: T
authors.initials: T
authors.lastname: Oka
authors.forename: K
authors.initials: K
authors.lastname: Sugano
mesh_terms: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D002455:Cell Division; D051546:Cyclooxygenase 2; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D005773:Gastroscopy; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D006965:Hyperplasia; D007527:Isoenzymes / Q000378:metabolism; D019394:Ki-67 Antigen / Q000378:metabolism; D008297:Male; D008565:Membrane Proteins; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*; D011127:Polyps / Q000150:complications / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D013274:Stomach Neoplasms / Q000150:complications / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*
chemical_list: D000900:Anti-Bacterial Agents; D000897:Anti-Ulcer Agents; D014408:Biomarkers, Tumor; D007527:Isoenzymes; D019394:Ki-67 Antigen; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D009853:Omeprazole